Oscar Health: 7X The Revenue Since Its IPO, And A Rerating Due In 2027

Impact · against what's priced in

The article presents a bullish case for Oscar Health based on market share gains and future EPS beats, but the primary catalysts are slated for 2027. Since the revenue growth and subsidy resilience are already reflected in the company's operational trajectory, the immediate impact is limited to the potential for a future valuation rerate.

OSCR+0.40

No priced-in read yet

In context

The company grew membership by 60% while the ACA market shrank 13%, suggesting resilience to subsidy expiration that could trigger a rerate in 2027 as consensus EPS lags management targets.

Read from the article alone

• earnings▲5%
• valuation▲4%
• revenue growth
• ipo
• OSCR
• aca
• health insurance
• subsidies